Leerink Partners Cuts Medtronic (NYSE:MDT) Price Target to $119.00

Medtronic (NYSE:MDT) had its price target dropped by equities research analysts at Leerink Partners from $120.00 to $119.00 in a research report issued to clients and investors on Wednesday,MarketScreener reports. The brokerage presently has an “outperform” rating on the medical technology company’s stock. Leerink Partners’ target price would indicate a potential upside of 23.75% from the company’s previous close.

Several other research analysts have also issued reports on the company. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the company a “neutral” rating in a report on Wednesday, November 19th. Citigroup started coverage on shares of Medtronic in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 price objective for the company. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. Finally, Barclays restated an “overweight” rating and set a $118.00 price target on shares of Medtronic in a research note on Wednesday. Sixteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and a consensus price target of $111.05.

Medtronic Trading Down 0.3%

NYSE:MDT traded down $0.25 during mid-day trading on Wednesday, hitting $96.16. 713,776 shares of the stock traded hands, compared to its average volume of 8,479,095. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. Medtronic has a 52 week low of $79.55 and a 52 week high of $106.33. The stock has a market capitalization of $123.28 billion, a price-to-earnings ratio of 25.92, a PEG ratio of 2.62 and a beta of 0.71. The firm’s 50 day moving average is $99.19 and its two-hundred day moving average is $96.58.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts predict that Medtronic will post 5.46 earnings per share for the current year.

Institutional Investors Weigh In On Medtronic

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AXQ Capital LP raised its stake in shares of Medtronic by 25.6% in the second quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock valued at $862,000 after acquiring an additional 2,013 shares in the last quarter. UMB Bank n.a. raised its holdings in Medtronic by 65.8% in the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock valued at $13,170,000 after acquiring an additional 54,898 shares in the last quarter. Applied Finance Capital Management LLC acquired a new position in Medtronic during the 3rd quarter worth approximately $1,308,000. Principal Financial Group Inc. raised its holdings in shares of Medtronic by 17.2% in the 3rd quarter. Principal Financial Group Inc. now owns 1,656,155 shares of the medical technology company’s stock valued at $157,732,000 after purchasing an additional 242,910 shares in the last quarter. Finally, Willis Investment Counsel lifted its position in shares of Medtronic by 5.0% during the 3rd quarter. Willis Investment Counsel now owns 401,868 shares of the medical technology company’s stock worth $38,274,000 after purchasing an additional 19,192 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat and reiterated guidance — Medtronic reported $9.02B revenue and $1.36 non‑GAAP EPS (above estimates) and reaffirmed FY26 EPS guidance, which supports near‑term visibility. PR Newswire: Medtronic Q3 Results
• Positive Sentiment: Cardio & diabetes momentum — Cardiovascular revenue up double digits with Cardiac Ablation Solutions up ~80% (U.S. up 137%); diabetes also showed mid‑single digit growth — key organic drivers for revenue upside. PR Newswire: Segment Growth
• Positive Sentiment: Regulatory/commercial catalysts — FDA clearances and first U.S. Hugo robotic‑assisted surgery performed at Cleveland Clinic (plus Infuse bone graft OK for TLIF and MiniMed Flex submission), which expand addressable markets. PR Newswire: Hugo first U.S. case
• Positive Sentiment: Analyst bullishness — TD Cowen reiterated a Buy with a $119 PT, and Needham kept a Buy at $120 (small PT trims), signaling continued analyst conviction behind the recovery thesis. TipRanks: TD Cowen reiterates Buy
• Neutral Sentiment: Technicals & positioning — Market commentary points to a bullish reversal pattern and heavy institutional accumulation; useful context for momentum traders but not a fundamental driver. MarketBeat: Textbook reversal
• Negative Sentiment: Price‑target cut / neutral rating from Baird — Robert W. Baird trimmed its PT to $100 and moved to Neutral, which could cap upside for some investors. Benzinga: Baird PT cut
• Negative Sentiment: Margin pressure & rising costs — Reports note profit fell on higher costs and tariff impacts; margin compression is a near‑term risk even as revenue grows. WSJ: Profit falls despite higher revenue

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).